<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466242</url>
  </required_header>
  <id_info>
    <org_study_id>17-193</org_study_id>
    <nct_id>NCT03466242</nct_id>
  </id_info>
  <brief_title>IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures</brief_title>
  <official_title>IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures. Timmons Z MD, Feudale B MD Children Presenting to the ED With Distal Forearm Extremity Fractures Often Require Re-alignment Under Conscious Sedation. The Objective of This Study is to Evaluate the Sedative, and Analgesic Effects of Intranasal (IN) Dexmedetomidine (DEX) Who Undergo Conscious Sedation for Reduction of Closed Distal Forearm Fractures When Compared to Those Receiving the Standard of Care Intravenous (IV) Ketamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the sedative, and analgesic effects of
      intranasal (IN) Dexmedetomidine (DEX) in children presenting to a Pediatric Emergency
      Department (PED) who undergo conscious sedation for reduction of closed distal forearm
      fractures when compared to those receiving intravenous (IV) Ketamine. The secondary objective
      is to compare each sedation technique for safety and procedural outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Distal Forearm fractures are often are displaced requiring conscious sedation for closed
      reduction in the Emergency Department. Our institution's current standard of care consists of
      IN Fentanyl for baseline control of pain, and for those fractures requiring reduction;
      typically IV Ketamine is utilized. Ketamine is typically well tolerated but is not without
      concerns including hypertension, vomiting, and the rare but serious complication of
      laryngospasm. Dexmedetomidine (DEX) offers a possible alternative to IV Ketamine. DEX has
      been used safely in the critical care setting for both pediatrics and adults. It has been
      well documented as being quite effective in sedation, amnesia and analgesia. Using IN DEX for
      PED procedural sedation has the potential to obviate the need for IV placement and may offer
      a better conscious sedation profile than Ketamine with respect to sedation, analgesia, and
      adverse outcomes.

      Our overall project would be to assess the efficiency of IN DEX in comparison to IV Ketamine,
      for proper sedation and analgesic coverage for children undergoing closed reduction of distal
      forearm fractures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a feasibility pilot study, and as such, will be non-blinded, and utilize a convenience sample of children aged 2-18 years old requiring closed reduction under conscious sedation for distal forearm fractures. 20 children recruited in IN Dex arm and 20 children in Ketamine arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the sedative effects of intranasal Dexmedetomidine in children undergoing conscious sedation for closed distal forearm fracture reduction compared to intravenous Ketamine</measure>
    <time_frame>12 months</time_frame>
    <description>The sedative effects of intranasal Dexmedetomidine will be compared to intravenous ketamine for conscious sedation via the Michigan Sedation Scoring (MSS) system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the analgesic effects of intranasal Dexmedetomidine in children undergoing conscious sedation for closed distal forearm fracture reduction compared to intravenous Ketamine</measure>
    <time_frame>12 months</time_frame>
    <description>The analgesic effects of intranasal Dexmedetomidine will be compared to intravenous ketamine for conscious sedation using either the Wong-Baker scale (FACES) or Visual Analogue Scale (VAS) depending on patient age and developmental status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for time to sedation onset</measure>
    <time_frame>12 months</time_frame>
    <description>Time in minutes and seconds from administration of sedative agent until Michigan Sedation Scoring (MSS) is 3 or higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for length of sedation</measure>
    <time_frame>12 months</time_frame>
    <description>Time in minutes and seconds from when Michigan Sedation Scoring (MSS) is 3 or higher until MSS is less than 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for length of ED stay</measure>
    <time_frame>12 months</time_frame>
    <description>Time in minutes and seconds from presentation to ED to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for need for additional doses of medications for analgesia or sedation</measure>
    <time_frame>12 months</time_frame>
    <description>Will measure if any unplanned doses of sedatives or analgesics are required in either treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for Vital sign abnormalities</measure>
    <time_frame>12 months</time_frame>
    <description>Review vital signs following administration of either study drug to see if any vital signs were abnormal. Abnormal vital signs will be defined as hear rate, respiratory rate, or blood pressure above or below one standard deviation for age derived norms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for need for respiratory interventions</measure>
    <time_frame>12 months</time_frame>
    <description>Measure if any respiratory interventions were required during the patient's ED stay. Respiratory interventions defined as need for oxygen by any device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for rate of vomiting</measure>
    <time_frame>12 months</time_frame>
    <description>Describe the incidence (yes/no) of vomiting at any point after administration of either study drug to ED discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for procedural success rate</measure>
    <time_frame>12 months</time_frame>
    <description>Describe the successful reduction of orthopedic injuries in each study arm. Successful reduction defined as patient able to be discharged and not requiring admission, surgery, or secondary reduction attempts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare each sedation technique for patient family satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>Describe the family satisfaction with each conscious sedation technique. Measured by brief survey given to the family upon consent for the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Conscious Sedation</condition>
  <condition>Distal Radius Fracture</condition>
  <arm_group>
    <arm_group_label>Intranasal Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine</description>
    <arm_group_label>Intranasal Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Evaluate sedative and analgesic effects of Intravenous Ketamine</description>
    <arm_group_label>IV Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Verbal children aged 2-18 with a single extremity displaced forearm
        fracture requiring conscious sedation and reduction will be screened for enrollment.

        Exclusion Criteria:

          1. Under age 2 years old or patients &gt; 18 years old

          2. Multiple Fractures

          3. Significant multisystem trauma

          4. Glasgow Coma Scale (GCS &lt; 15)

          5. Complex fractures that aren't deemed reducible in ED

          6. Reported Allergy to Alpha -2-agonists

          7. Pregnancy

          8. Intoxication

          9. Baseline Hypotension as &lt; 70mm Hg + 2 x age or &lt; 90mm Hg for patients &gt; 11 years of
             age

         10. Patients with prior reductions attempted at outside facilities

         11. Aberrant nasal anatomy that precludes IN medications

         12. Chronic Health issues that can affect DEX metabolism

         13. History of adverse reactions to anesthesia

         14. Patients transferred from outside facilities

         15. Open fractures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zebulon Timmons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zebulon Timmons, MD</last_name>
    <phone>602-933-1910</phone>
    <email>ztimmons@phoenixchildrens.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brent Feudale, MD</last_name>
    <phone>602-933-1910</phone>
    <email>bfeudale@phoenixchildrens.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zebulon Timmons, MD</last_name>
      <phone>602-933-1910</phone>
      <email>ztimmons@phoenixchildrens.com</email>
    </contact>
    <contact_backup>
      <last_name>Brent Feudale, MD</last_name>
      <phone>602-933-1910</phone>
      <email>bfeudale@phoenixchildrens.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Landin LA. Epidemiology of children's fractures. J Pediatr Orthop B. 1997 Apr;6(2):79-83.</citation>
    <PMID>9165435</PMID>
  </results_reference>
  <results_reference>
    <citation>Gausche-Hill M, Brown KM, Oliver ZJ, Sasson C, Dayan PS, Eschmann NM, Weik TS, Lawner BJ, Sahni R, Falck-Ytter Y, Wright JL, Todd K, Lang ES. An Evidence-based Guideline for prehospital analgesia in trauma. Prehosp Emerg Care. 2014;18 Suppl 1:25-34. doi: 10.3109/10903127.2013.844873. Epub 2013 Nov 26.</citation>
    <PMID>24279813</PMID>
  </results_reference>
  <results_reference>
    <citation>Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007 Mar;49(3):335-40. Epub 2006 Oct 25.</citation>
    <PMID>17067720</PMID>
  </results_reference>
  <results_reference>
    <citation>Litke J, Pikulska A, Wegner T. Management of perioperative stress in children and parents. Part I--the preoperative period. Anaesthesiol Intensive Ther. 2012 Jul-Sep;44(3):165-9. Review.</citation>
    <PMID>23110295</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhat R, Santhosh MC, Annigeri VM, Rao RP. Comparison of intranasal dexmedetomidine and dexmedetomidine-ketamine for premedication in pediatrics patients: A randomized double-blind study. Anesth Essays Res. 2016 May-Aug;10(2):349-55. doi: 10.4103/0259-1162.172340.</citation>
    <PMID>27212773</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller K, Tan X, Hobson AD, Khan A, Ziviani J, OʼBrien E, Barua K, McBride CA, Kimble RM. A Prospective Randomized Controlled Trial of Nonpharmacological Pain Management During Intravenous Cannulation in a Pediatric Emergency Department. Pediatr Emerg Care. 2016 Jul;32(7):444-51. doi: 10.1097/PEC.0000000000000778.</citation>
    <PMID>27380603</PMID>
  </results_reference>
  <results_reference>
    <citation>Fowler-Kerry S, Lander JR. Management of injection pain in children. Pain. 1987 Aug;30(2):169-75.</citation>
    <PMID>3670868</PMID>
  </results_reference>
  <results_reference>
    <citation>Kogan A, Katz J, Efrat R, Eidelman LA. Premedication with midazolam in young children: a comparison of four routes of administration. Paediatr Anaesth. 2002 Oct;12(8):685-9.</citation>
    <PMID>12472704</PMID>
  </results_reference>
  <results_reference>
    <citation>Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT. Bioavailability of dexmedetomidine after intranasal administration. Eur J Clin Pharmacol. 2011 Aug;67(8):825-31. doi: 10.1007/s00228-011-1002-y. Epub 2011 Feb 12.</citation>
    <PMID>21318594</PMID>
  </results_reference>
  <results_reference>
    <citation>Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs. 2008;10(1):49-69. Review.</citation>
    <PMID>18162008</PMID>
  </results_reference>
  <results_reference>
    <citation>Behrle N, Birisci E, Anderson J, Schroeder S, Dalabih A. Intranasal Dexmedetomidine as a Sedative for Pediatric Procedural Sedation. J Pediatr Pharmacol Ther. 2017 Jan-Feb;22(1):4-8. doi: 10.5863/1551-6776-22.1.4.</citation>
    <PMID>28337075</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yao TJ, Wong GL, Yuen MK. Optimal timing for the administration of intranasal dexmedetomidine for premedication in children. Anaesthesia. 2010 Sep;65(9):922-9. doi: 10.1111/j.1365-2044.2010.06453.x.</citation>
    <PMID>20645951</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.</citation>
    <PMID>22950484</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller JW, Divanovic AA, Hossain MM, Mahmoud MA, Loepke AW. Dosing and efficacy of intranasal dexmedetomidine sedation for pediatric transthoracic echocardiography: a retrospective study. Can J Anaesth. 2016 Jul;63(7):834-41. doi: 10.1007/s12630-016-0617-y. Epub 2016 Feb 16.</citation>
    <PMID>26883963</PMID>
  </results_reference>
  <results_reference>
    <citation>Reynolds J, Rogers A, Capehart S, Manyang P, Watcha MF. Retrospective Comparison of Intranasal Dexmedetomidine and Oral Chloral Hydrate for Sedated Auditory Brainstem Response Exams. Hosp Pediatr. 2016 Mar;6(3):166-71. doi: 10.1542/hpeds.2015-0152.</citation>
    <PMID>26917547</PMID>
  </results_reference>
  <results_reference>
    <citation>Malhotra PU, Thakur S, Singhal P, Chauhan D, Jayam C, Sood R, Malhotra Y. Comparative evaluation of dexmedetomidine and midazolam-ketamine combination as sedative agents in pediatric dentistry: A double-blinded randomized controlled trial. Contemp Clin Dent. 2016 Apr-Jun;7(2):186-92. doi: 10.4103/0976-237X.183058.</citation>
    <PMID>27307665</PMID>
  </results_reference>
  <results_reference>
    <citation>Li BL, Zhang N, Huang JX, Qiu QQ, Tian H, Ni J, Song XR, Yuen VM, Irwin MG. A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops. Anaesthesia. 2016 May;71(5):522-8. doi: 10.1111/anae.13407. Epub 2016 Mar 3.</citation>
    <PMID>26936022</PMID>
  </results_reference>
  <results_reference>
    <citation>Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705.</citation>
    <PMID>10702460</PMID>
  </results_reference>
  <results_reference>
    <citation>Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000 Aug;93(2):382-94.</citation>
    <PMID>10910487</PMID>
  </results_reference>
  <results_reference>
    <citation>Olutoye O, Kim T, Giannoni C, Stayer S. Dexmedetomidine as an analgesic for pediatric tonsillectomy and adenoidectomy. Paediatr Anaesth. 2007 Oct;17(10):1007-8.</citation>
    <PMID>17767643</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15.</citation>
    <PMID>24237879</PMID>
  </results_reference>
  <results_reference>
    <citation>Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014 Feb;77(2):357-67. doi: 10.1111/bcp.12094. Review.</citation>
    <PMID>23432384</PMID>
  </results_reference>
  <results_reference>
    <citation>Lightdale JR, Mitchell PD, Fredette ME, Mahoney LB, Zgleszewski SE, Scharff L, Fox VL. A Pilot Study of Ketamine versus Midazolam/Fentanyl Sedation in Children Undergoing GI Endoscopy. Int J Pediatr. 2011;2011:623710. doi: 10.1155/2011/623710. Epub 2011 May 16.</citation>
    <PMID>21760813</PMID>
  </results_reference>
  <results_reference>
    <citation>Rasmussen KG. Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control. Acta Neuropsychiatr. 2014 Aug;26(4):230-3. doi: 10.1017/neu.2013.61.</citation>
    <PMID>25142291</PMID>
  </results_reference>
  <results_reference>
    <citation>Parvizrad R, Pakniyat A, Malekianzadeh B, Almasi-Hashiani A. Comparing the analgesic effect of intranasal with intravenous ketamine in isolated orthopedic trauma: A randomized clinical trial. Turk J Emerg Med. 2017 Jun 23;17(3):99-103. doi: 10.1016/j.tjem.2017.05.006. eCollection 2017 Sep.</citation>
    <PMID>28971157</PMID>
  </results_reference>
  <results_reference>
    <citation>Jonkman K, Dahan A, van de Donk T, Aarts L, Niesters M, van Velzen M. Ketamine for pain. F1000Res. 2017 Sep 20;6. pii: F1000 Faculty Rev-1711. doi: 10.12688/f1000research.11372.1. eCollection 2017. Review.</citation>
    <PMID>28979762</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phoenix Children's Hospital</investigator_affiliation>
    <investigator_full_name>Zebulon Timmons</investigator_full_name>
    <investigator_title>Zebulon Timmons, MD Vice section Chair of Emergency</investigator_title>
  </responsible_party>
  <keyword>intranasal dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Radius Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

